- Home
- BUDA vs COEP Comparison
BUDA vs COEP Comparison
Compare BUDA & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUDA | COEP |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 100.4M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | BUDA | COEP |
|---|---|---|
| Price | $9.10 | $11.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.1K | ★ 62.4K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $12,486,000.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.24 | ★ N/A |
| Revenue Growth | ★ 33.11 | N/A |
| 52 Week Low | $6.85 | $6.26 |
| 52 Week High | $12.00 | $21.41 |
Technical Indicators
Market Signals| Indicator | BUDA | COEP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 32.99 |
| Support Level | N/A | $10.49 |
| Resistance Level | N/A | $15.94 |
| Average True Range (ATR) | 0.00 | 1.21 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 0.00 | 9.91 |
Price Performance
Historical ComparisonAbout BUDA Buda Juice Inc. Common Stock
Buda Juice Inc operates in a competitive beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never pasteurized, never HPP- processed, never UV- treated and always cold.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.